Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received an average recommendation of “Buy” from the ten analysts that are presently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $45.00.
A number of analysts recently commented on DNTH shares. Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price target for the company. Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating for the company. Raymond James raised their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research report on Thursday, April 18th. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, HC Wainwright initiated coverage on Dianthus Therapeutics in a research report on Thursday, May 16th. They set a “buy” rating and a $40.00 price objective for the company.
Check Out Our Latest Analysis on DNTH
Hedge Funds Weigh In On Dianthus Therapeutics
Dianthus Therapeutics Stock Up 3.2 %
Shares of DNTH stock opened at $28.36 on Tuesday. The stock has a fifty day moving average of $25.90 and a 200 day moving average of $24.78. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77. The firm has a market capitalization of $832.37 million, a price-to-earnings ratio of -4.86 and a beta of 1.89.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The company had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.48 million. Equities research analysts anticipate that Dianthus Therapeutics will post -2.18 earnings per share for the current year.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Recommended Stories
- Five stocks we like better than Dianthus Therapeutics
- How Technical Indicators Can Help You Find Oversold StocksÂ
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- The Most Important Warren Buffett Stock for Investors: His Own
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- The 3 Best Retail Stocks to Shop for in August
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.